ER/LA Opioid REMS Program Companies (RPC)
6
0
0
0
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 6 trials
0%
0 trials in Phase 3/4
0%
0 of 0 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (6)
Evaluation of Drug Utilization Patterns for Extended Release/Long Acting Opioids and Comparator Products
Role: lead
ER/LA Opioid Surveillance for Emergency Department Visits and Hospitalizations for Overdose and Poisoning
Role: lead
Monitoring Patterns of Prescribing to Identify Changes in Access to ER/LA Opioid Analgesics
Role: lead
Evaluation of Changes in Prescribing Behavior of ER/LA Opioid Prescribers
Role: lead
ER/LA Opioid Analgesics - Surveillance Monitoring of State Medical Examiner Databases
Role: lead
Surveillance Monitoring of Opioid Abuse in Poison and Drug Treatment Centers
Role: lead
All 6 trials loaded